Skip to main content

Table 2 Parameters for all patients before and after TCZ treatment

From: Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET/CT

 

Before treatment

After 3M treatment

After 6M treatment

All patients

All patients

All patients

 

Mean ± SD (range)

Mean ± SD (range)

Mean ± SD (range)

DAS28

4.7±1.4 (2.5-8.9)

3.2±1.5 (1.3-6.3)*

3.1±1.6 (0.9-6.7)*

DAS28-CRP

3.2±1.4 (1.3-8.9)

2.4±1.3 (1.0-5.2)*

2.4±1.4 (1.0-5.2)*

SDAI

20.2±16.6 (3.2-75.1)

10.4±10.8 (0.7-40.9)*

11.7±13.3 (0.1-42.8)*

CDAI

18.1±15.4 (2.8-68)

9.8±10.0 (0.7-39)*

11.1±13.0 (0.1-42.8)*

ESR (mm/h)

67.8±33.9 (14–122)

23.4±26.0 (3–107)*

20.9±25.0 (2–98)*

CRP (mg/dl)

2.16±2.72 (0.11-7.10)

0.60±1.48 (0.01-5.73)*

0.53±1.55 (0.00-6.25)*

MMP-3 (ng/ml)

302.6±254.2 (28.4-792.6)

150.1±153.4 (32.1-600.7)*

139.6±152.3 (10.0-545.4)*

Tender joints count

3.6±5.9 (0–24)

2.5±3.6 (0–13)

2.9±5.0 (0–18)

Swollen joints count

5.7±5.8 (0–24)

3.1±3.6 (0–15)*

3.8±4.9 (0–15)

P-VAS

39.9±29.0 (0–100)

22.5±24.1 (0–70)*

23.0±24.1 (0–71)*

E-VAS

47.9±26.9 (0–100)

19.4±15.9 (0–55)*

20.5±21.8 (1–77)*

  1. The data are presented as the mean (S.D.) (range). The average for each parameter was calculated before treatment and at follow-up.
  2. *indicates a significant difference compared with the value observed at baseline (p < 0.05). P-VAS: patient global disease activity represented by the visual analog scale. E-VAS: evaluator global disease activity represented by the visual analog scale.